Esophagogastric Cancer Clinical Trial
Official title:
Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer
The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject or legally authorized representative is willing and able to provide written informed consent. - Patients with previously treated metastatic or unresectable histologically-confirmed esophagogastric cancer who have received at least 1 line of therapy. - EGFR or MET amplification by tissue-NGS with copy number >8 and/or ctDNA amplification by any FDA and CLIA-approved assay - No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer. (Note: if a patient previously received a EGFR inhibitor, but subsequently demonstrated a MET amplification, or previously received a MET inhibitor, but subsequently demonstrated an EGFR-amplification, inclusion is permitted). - Patients with HER2+ (IHC 3+ or IHC 2+/FISH+) tumors must have progressed on trastuzumab. - Measurable disease based on RECIST 1.1. - = 18 years of age on day of signing informed consent. - Have an ECOG performance status of 0, 1, or 2. - Adequate organ function, defined as: A. Hemoglobin =9 g/dL B. ANC =1.0 x 10^9 /L C. Platelets =75 x 10^9 /L D. AST and ALT =3 x ULN (=5 x ULN for subjects with liver metastases) E. Total bilirubin =1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits F. Serum creatinine <1.5 x ULN or if available, calculated or measured creatinine clearance >50 mL/min/1.73 m^2 - Women of childbearing potential and male patients with women of childbearing potential partners must be willing to use an adequate method of contraception Exclusion Criteria: - Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia). - If subject received major surgery, they must have recovered adequately prior to starting therapy. - Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. - Known active hepatitis B (e.g., HBsAg reactive or polymerase chain reaction detectable). Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing. - Known active hepatitis C (e.g., HCV RNA [qualitative] is detected). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible. - Other clinically active or chronic liver disease. - Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded. - Pulmonary embolism (PE) and deep vein thrombosis (DVT), within 1 month of start of study drug. - Myocardial infarction, unstable angina, stroke, transient ischemic attach (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug. - Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of start of study drug. - Interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months. - Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment. - Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator. - Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment. - Prisoners, or subjects who are compulsory detained. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Basking Ridge (Limited protocol activities) | Basking Ridge | New Jersey |
United States | Massachusetts General Hospital (Data Collection Only) | Boston | Massachusetts |
United States | Memorial Sloan Kettering Commack (Limited Protocol Activities) | Commack | New York |
United States | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York |
United States | University of California, Irvine | Irvine | California |
United States | Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown | New Jersey |
United States | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey |
United States | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York |
United States | Memorial Sloan Kettering Nassau (Limited protocol activities) | Rockville Centre | New York |
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Janssen Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | objective response rate | ORR; defined as complete response (CR) or partial response (PR)) by RECIST 1.1 criteria | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05612048 -
A Study of Tooth Erosion in People With Esophagogastric Cancer
|
N/A | |
Completed |
NCT04161781 -
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
||
Completed |
NCT01803282 -
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05796102 -
PET-MRI Esophagus Feasibility Study
|
N/A | |
Recruiting |
NCT04656041 -
Folfox+Irinotecan+Chemort In Esophageal Cancer
|
Phase 2 | |
Withdrawn |
NCT02296671 -
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
|
Phase 2 | |
Active, not recruiting |
NCT04757363 -
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
|
Phase 2 | |
Completed |
NCT02023996 -
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
|
N/A | |
Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
Completed |
NCT01167114 -
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03133650 -
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
|
Phase 1 |